Volume Overload in Cardiac Amyloidosis: The Role of Loop Diuretics 1. Introduction Cardiac amyloidosis (CA) is a group of infiltrative […]

Dietary Management in Cardiac Amyloidosis: Sodium and Fluid Limitations in Heart Failure 1. Introduction CA is a restrictive cardiomyopathy defined

SGLT2 Inhibitors in Cardiac Amyloidosis: Emerging Benefits and Tolerability 1. Introduction Cardiac amyloidosis (CA) is a restrictive cardiomyopathy due to

Challenges of Guideline-Directed Medical Therapy in Cardiac Amyloidosis 1. Introduction Cardiac amyloidosis (CA) is a severe form of systemic amyloidosis,

Beta-Blockers in Cardiac Amyloidosis: Benefits, Risks, and Clinical Considerations 1. Introduction Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy due to

Heart Failure in Cardiac Amyloidosis: Understanding HFpEF and HFrEF 1. Introduction Cardiac amyloidosis (CA) is a severe expression of systemic

Eight Clinical Domains of Supportive Care in Systemic Amyloidosis: ISA Guidelines Explained 1. Introduction Systemic amyloidosis is a rare and

Multidisciplinary Approach: The Way Forward in the Management of Systemic Amyloidosis Patients 1. Introduction Systemic amyloidosis is a multisystem, complex

Treatment of Systemic Amyloidosis: Primary Aim, Strategy, and Patient Management 1. Introduction Systemic amyloidosis is a category of uncommon yet

Why Supportive Care is Critical in Systemic Amyloidosis Management 1. Introduction Systemic amyloidosis is a rare but severe disorder in